# Phase 1/2 glioma trials recruiting: 30 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 30 trials in phase 1/2 for glioma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 glioma trials: 30 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/glioma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 30
- Recruiting or not yet: 30
- Read on: November 19, 2026

## Trials

The 25 newest of 30, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 5, 2026 | NCT07859059 | Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma | University of Nebraska | Phase 1/2 | Not yet recruiting | High Grade Glioma, Glioblastoma, Gliosarcoma | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859059) |
| August 17, 2026 | NCT07767110 | Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of Response | NanOlogy, LLC (doing business as Intryx Therapeutics, LLC) | Phase 1/2 | Not yet recruiting | Diffuse Midline Glioma (DMG), Diffuse Intrinsic Pontine Glioma (DIPG), Diffuse Midline Glioma or Diffuse Intrinsic... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07767110) |
| August 7, 2026 | NCT07751744 | Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal... | Jubilant Therapeutics Inc. | Phase 1/2 | Not yet recruiting | Brain Metastases From Solid Tumors, Leptomeningeal Disease, High Grade Glioma (HGG), Glioblastoma (GBM) | 113 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751744) |
| May 20, 2026 | NCT07599371 | A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of... | The First Affiliated Hospital of Zhengzhou University | Phase 1/2 | Recruiting | Relapsed/Refractory Glioma | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07599371) |
| May 5, 2026 | NCT07567469 | A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma... | Regeneron Pharmaceuticals | Phase 1/2 | Not yet recruiting | High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07567469) |
| April 20, 2026 | NCT07539441 | A Study of Mirdametinib in People With Central Nervous System Tumors | Memorial Sloan Kettering Cancer Center | Phase 1/2 | Recruiting | Central Nervous System Tumors, Glioma | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07539441) |
| March 30, 2026 | NCT07501156 | H3K27M-specific Immune Effector Cells Targeting DMG/DIPG | Shenzhen Geno-Immune Medical Institute | Phase 1/2 | Not yet recruiting | Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07501156) |
| March 12, 2026 | NCT07468136 | Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas | Mayo Clinic | Phase 1/2 | Recruiting | Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Diffuse Astrocytoma... | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07468136) |
| February 18, 2026 | NCT07416188 | Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1/2 | Recruiting | Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Relapsed Cancer, Recurrent Tumor... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07416188) |
| February 5, 2026 | NCT07389278 | Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) | Sponsor not shown (see the record) | Phase 1/2 | Not yet recruiting | Glioblastoma, High-Grade Glioma (WHO III-IV), High-grade Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse... | 97 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07389278) |
| November 24, 2025 | NCT07243470 | Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors | Centre Leon Berard | Phase 1/2 | Recruiting | Glioma, CNS Tumor, Adult, CNS Tumor, Childhood | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07243470) |
| November 21, 2025 | NCT07243340 | A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor | ImmVira Pharma Co. Ltd | Phase 1/2 | Recruiting | Glioma, Malignant | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07243340) |
| February 5, 2025 | NCT06810544 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | Tango Therapeutics, Inc. | Phase 1/2 | Recruiting | Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor, Non-Small Cell... | 191 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06810544) |
| December 2, 2024 | NCT06712875 | MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas | Ann & Robert H Lurie Children's Hospital of Chicago | Phase 1/2 | Recruiting | Low Grade Glioma, High Grade Glioma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06712875) |
| November 25, 2024 | NCT06703255 | A Phase 2 Study of HX301 in Patients with High-grade Giloma | Hangzhou Hanx Biopharmaceuticals, Ltd. | Phase 1/2 | Recruiting | Glioma | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06703255) |
| October 15, 2024 | NCT06640582 | TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas | Essen Biotech | Phase 1/2 | Recruiting | Brain Tumor, Brain Metastases, Brain Cancer, Glioma, Gliomas, Malignant, Glioblastoma, Meningioma | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06640582) |
| September 23, 2024 | NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent... | Fundación de investigación HM | Phase 1/2 | Recruiting | Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas, Meningioma, Paraganglioma... | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06607692) |
| July 16, 2024 | NCT06504381 | DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma | University of California, San Francisco | Phase 1/2 | Recruiting | High Grade Glioma, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06504381) |
| June 18, 2024 | NCT06465199 | Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas | Milton S. Hershey Medical Center | Phase 1/2 | Recruiting | Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Multilayered Rosettes, Ewing Sarcoma, Diffuse Intrinsic Pontine... | 265 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06465199) |
| February 14, 2024 | NCT06258018 | Niraparib and Temozolomide in Patients Glioblastoma | Sponsor not shown (see the record) | Phase 1/2 | Not yet recruiting | Glioma, Malignant | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06258018) |
| December 8, 2023 | NCT06161519 | PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Glioma, Medulloblastoma, Ependymoma, Glioblastoma | 146 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06161519) |
| July 21, 2023 | NCT05956821 | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | University of Miami | Phase 1/2 | Recruiting | Glioblastoma Multiforme, Anaplastic Astrocytoma, Fibrillary Astrocytomas, Oligodendroglioma, Diffuse Intrinsic... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05956821) |
| October 20, 2022 | NCT05588141 | 000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Brain Tumor, Cancer | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05588141) |
| June 14, 2022 | NCT05417594 | Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies | AstraZeneca | Phase 1/2 | Recruiting | Advanced Solid Malignancies | 695 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05417594) |
| March 14, 2022 | NCT05278208 | Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | Nationwide Children's Hospital | Phase 1/2 | Recruiting | High Grade Glioma, Meningioma, Embryonal Tumor, Medulloblastoma, Anaplastic Ependymoma, Recurrent Diffuse Intrinsic... | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05278208) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 2 |
| Centre Leon Berard | 1 |
| Ann & Robert H Lurie Children's Hospital of Chicago | 1 |
| University of Nebraska | 1 |
| NanOlogy, LLC (doing business as Intryx Therapeutics, LLC) | 1 |
| Milton S. Hershey Medical Center | 1 |
| Jubilant Therapeutics Inc. | 1 |
| University of California, San Francisco | 1 |
| ImmVira Pharma Co. Ltd | 1 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 1 |
| Nationwide Children's Hospital | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| The First Affiliated Hospital of Zhengzhou University | 1 |
| Mayo Clinic | 1 |
| Hangzhou Hanx Biopharmaceuticals, Ltd. | 1 |
| Turning Point Therapeutics, Inc. | 1 |
| Stanford University | 1 |
| Tango Therapeutics, Inc. | 1 |
| Laminar Pharmaceuticals | 1 |
| Fundación de investigación HM | 1 |
| Children's Oncology Group | 1 |
| University of Miami | 1 |
| Shenzhen Geno-Immune Medical Institute | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 19 |
| China | 5 |
| Australia | 3 |
| Spain | 3 |
| France | 2 |
| Italy | 2 |
| South Korea | 2 |
| United Kingdom | 2 |
| Canada | 1 |
| Denmark | 1 |
| Singapore | 1 |
| Taiwan | 1 |
| Germany | 1 |
| Sweden | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Medical research institutes in the United States](https://specstream.ai/data/businesses/medical-research-institutes/united-states)
- [Metal suppliers in the United States](https://specstream.ai/data/businesses/metal-suppliers/united-states)
- [Motorcycle manufacturers in the United States](https://specstream.ai/data/businesses/motorcycle-manufacturers/united-states)
- [Nursing services in the United States](https://specstream.ai/data/businesses/nursing-services/united-states)
- [Orthodontics practices in the United States](https://specstream.ai/data/businesses/orthodontics-practices/united-states)
- [Pakistani restaurants in the United States](https://specstream.ai/data/businesses/pakistani-restaurants/united-states)
